by Brendan Abel, JD Countless regulations have been enacted over the past 35 years to protect children from unnecessary clinical testing. Federal regulations, the Belmont Report, and professional guidelines all state that children should be…
Friday, November 2, 2012 8:30am – 6:30pm (reception to follow) Milstein Conference Rooms, 2nd Floor Wasserstein Hall 1585 Massachusetts Avenue Cambridge, MA Just a reminder that next week the Petrie-Flom Center and the Edmond J. Safra Center for…
By Leslie P. Francis On October 4, four Republican Congressman, all with powerful positions concerning health care, wrote Secretary Sebelius urging suspension of “meaningful use” Stage 2 payments until a stronger program is in place.…
By Nicole Huberfeld Two vaguely related thoughts on the future of the ACA. First, when I present my co-authored Medicaid post-mortem paper forthcoming in B.U. L. Rev., I find I am frequently asked “what could…
By David Orentlicher While it is important for people to express their wishes about end-of-life care in advance, a court case in Hawaii reminds us that advance directives do not always ensure that patient’s wishes…
By Katharine Van Tassel The University of Georgia School of Law seeks a tenure-track assistant professor to serve as the director of a to-be-created Medical-Legal Partnership (MLP) Clinic, beginning the 2013 – 2014 academic year.…
By Hyeongsu Park and Kathy Wang In England, a High Court judge ruled that a profoundly brain damaged 3-year-old boy in foster care should not be given life support when his condition deteriorates, despite the…
It’s Friday again! Enjoy the Yale Friday Newsletter (edited for our readership), with lots of great items this week.
By Nicolas Terry Tim Jost, The Internal Revenue Service’s Implementation and Administration of the Democrat’s Health Care Law, SSRN/Hastings Center Report Leslie Francis, When Patients Interact with EHRs: Problems of Privacy and Confidentiality, SSRN/Houston Journal of…
by Jonathan J. Darrow On October 3, 2012, the FDA’s Division of Professional Drug Promotion issued an untitled letter to Genentech in connection with its cancer drug Tarceva. Tarceva (erlotinib) was approved in 2004 for…
